Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 906 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65 - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT06851988Recruiting
Can exercise boost immunity and reduce head and neck cancer relapse?
This study tests whether a supervised exercise program can boost your immune system and lower the chances of cancer coming back after chemoradiation for head and neck cancer.
New Taipei CityAges 20–80 - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06863259RecruitingPhase 1
Study of a drug combo for relapsed B-cell leukemia
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
Cincinnati, OhioAges 1–39 - NCT06863974Recruiting
Finding markers of relapsing nerve inflammation in children
This study looks at children who have had a first attack of nerve inflammation (like ADEM, vision loss, or spinal cord issues) to find markers in the blood that might show if it will come back. It tests blood and cells to better understand the immune response.
AngersAges 18 years+ - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06883526RecruitingPhase 1/Phase 2
ZG005 plus gecacitinib for lymphoma that has returned or not responded
This trial tests a combination of two drugs, ZG005 and gecacitinib, for people with lymphoma that has come back or hasn't gotten better with prior treatment. The goal is to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT06894602Recruiting
Can Ultrasound Predict Relapse in Giant Cell Arteritis?
This study uses an ultrasound of the temporal artery (a vessel in your temple) to see if certain findings can predict whether giant cell arteritis will come back. It may help doctors know who needs closer monitoring.
BrestAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Beverly Hills, CaliforniaAges 18 years+ - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT06919900Recruiting
Learning fall-resistant skills in multiple sclerosis
This trial tests if practicing slips and trips can help people with multiple sclerosis learn to prevent falls. You will be exposed to controlled slips and trips to improve your balance and walking safety.
Atlanta, GeorgiaAges 45–89 - NCT06920251RecruitingPhase 2
Preventing CMV Infection During Elranatamab Treatment for Myeloma
This trial tests whether giving letermovir (a medication to prevent CMV infection) is safe and effective for people with relapsed/refractory multiple myeloma who are starting elranatamab therapy. It is for patients who have already had several prior treatments and have been exposed to CMV in the past.
SeoulAges 19 years+
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 906 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.